Covid‐19 vaccines and variants of concern: A review

@article{HadjHassine2021Covid19VA,
  title={Covid‐19 vaccines and variants of concern: A review},
  author={Ikbel Hadj Hassine},
  journal={Reviews in Medical Virology},
  year={2021},
  volume={32}
}
Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid‐19 vaccine candidates based on the original Wuhan‐Hu‐1 strain are at the forefront of vaccine research. All nine had an efficacy over 50% against symptomatic Covid‐19 disease: NVX‐CoV2373 (∼96%), BNT162b2 (∼95… 

COVID-19 Vaccines: Current and Future Perspectives

TLDR
The limits of vaccines developed against COVID-19 are discussed and possible innovative approaches are discussed, including strict storage at low temperatures for some vaccines and challenges regarding logistic problems.

Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review

The global pandemic of COVID‐19 began in December 2019 and is still continuing. The past 2 years have seen the emergence of several variants that were more vicious than each other. The emergence of

Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy

TLDR
The analysis demonstrates that the titer of antibodies directed towards the receptor-binding domain (RBD) of SARS-CoV-2 Spike is significantly associated with age and vaccine type, and the use of rapid devices to detect the presence of neutralizing antibodies appears helpful in determining the duration of the humoral protection elicited by vaccination.

Current challenges in different approaches to control COVID-19: a comprehensive review

TLDR
This review highlights the international situation, risk factors, and related protections to be taken as prerequisite measures and probable treatment options for the COVID-19-infected population in the current scenario.

Title : Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of 1 Unvaccinated and Vaccinated U . S . Military Personnel 2

TLDR
This study analyzed nasal swab samples collected from a cohort of United States military personnel and healthcare system beneficiaries and found that the Delta variant is the predominant strain circulating among U.S. military personnel beginning in July 2021 and primarily represents cases of vaccine-related breakthrough infections.

From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?

TLDR
The structural features of both the Spike protein and the Mpro of the recently reported SARS-CoV-2 variant XE, as well the closely related XD and XF ones are analyzed, discussing their impact on the efficacy of existing treatments against COVID-19 and on the development of future ones.

Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of Unvaccinated and Vaccinated U.S. Military Personnel

TLDR
This study analyzed nasal swab samples collected from a cohort of United States military personnel and healthcare system beneficiaries stationed worldwide and found that the Delta variant is the predominant strain circulating among U.S. military personnel beginning in July 2021 and primarily represents cases of vaccine breakthrough infections (VBIs).

DDDT_A_347297 951..972

TLDR
Personalized cocktails of immunotherapeutics and CRISPR Cas systems against COVID-19 as a strategy might prevent further disease progression and circumvent immunity escape.

References

SHOWING 1-10 OF 160 REFERENCES

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

TLDR
This review will focus on the eight vaccine candidates that entered Phase 1 clinical trials in mid-May, including AstraZeneca/Oxford's AZD1222, Moderna's mRNA-1273 and Sinovac's CoronaVac vaccines, which are currently in advanced stages of vaccine development.

One year update on the COVID-19 pandemic: Where are we now?

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

TLDR
The data suggest that control of some emergent SARS-CoV-2 variants may benefit from updated vaccines, including the Gamaleya Sputnik V Ad26 / Ad5 vaccine.

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

TLDR
A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.7 variant, and had a reassuring safety profile.

Current advances in the development of SARS-CoV-2 vaccines

TLDR
The current status of vaccine development against clinically relevant Sars-CoV-2 strains is outlined, anticipating that such attempts would help create efficacious and sage SARS-Cov-2 vaccines.

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

TLDR
A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B. 1.1.351 variant, and this variant showed greater resistance to the pseudovirus and the live-virus neutralization assays than in samples from placebo recipients.

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.

The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.

TLDR
It has been reported that the British variant that increases viral load does not cause more severe effects in the respiratory tract and lung disease, therefore, it is certain that the variant is growing rapidly and must be kept under control; for this reason, laboratory data is expected impatiently.

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

TLDR
Additional safety and immunogenicity data from the US Phase 1 trial supported selection of the BNT162b2 vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation, currently underway.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
...